{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:08Z","timestamp":1786982768044,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40262-022-01145-y","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T14:03:57Z","timestamp":1656425037000},"page":"1095-1114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical Pharmacokinetics of Metoprolol: A Systematic Review"],"prefix":"10.1007","volume":"61","author":[{"given":"Ammara","family":"Zamir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltaf","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees","family":"ur Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faleh","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-8583","authenticated-orcid":false,"given":"Muhammad Fawad","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"1145_CR1","unstructured":"Metoprolol. [cited; Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Metoprolol. Accessed 10 Oct 2021."},{"key":"1145_CR2","doi-asserted-by":"crossref","unstructured":"Brogden RN, Heel RC, Speight TM, Avery GS. Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1977;14(5):321\u201348.","DOI":"10.2165\/00003495-197714050-00001"},{"key":"1145_CR3","volume-title":"Metoprolol","author":"J Morris","year":"2018","unstructured":"Morris J, Dunham A. Metoprolol. Treasure Island: StatPearls Publishing; 2018."},{"issue":"1","key":"1145_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/ICB.0000000000000917","volume":"16","author":"R Jorge","year":"2022","unstructured":"Jorge R, Chaves L, da Silva CA, et al. Alternative management of circumscribed choroidal hemangioma using intravitreal metoprolol. Retinal Cases Brief Reports. 2022;16(1):106\u201310.","journal-title":"Retinal Cases Brief Reports"},{"issue":"1","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1208\/s12248-008-9023-x","volume":"10","author":"M Tubic-Grozdanis","year":"2008","unstructured":"Tubic-Grozdanis M, Bolger MB, Langguth P, et al. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J. 2008;10(1):213\u201326.","journal-title":"AAPS J"},{"issue":"6","key":"1145_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2165\/00003088-198005060-00004","volume":"5","author":"C-G Reg\u00e5rdh","year":"1980","unstructured":"Reg\u00e5rdh C-G, Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet. 1980;5(6):557\u201369.","journal-title":"Clin Pharmacokinet"},{"key":"1145_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fphar.2018.00774","volume":"9","author":"B Berger","year":"2018","unstructured":"Berger B, Bachmann F, Duthaler U, et al. Cytochrome P450 enzymes involved in metoprolol metabolism and use of metoprolol as a CYP2D6 phenotyping probe drug. Front Pharmacol. 2018;9:774.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1208\/s12248-009-9107-2","volume":"11","author":"V Lukacova","year":"2009","unstructured":"Lukacova V, Woltosz WS, Bolger MB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J. 2009;11(2):323\u201334.","journal-title":"AAPS J"},{"issue":"1","key":"1145_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40246-020-00260-w","volume":"14","author":"CN Brocker","year":"2020","unstructured":"Brocker CN, Velenosi T, Flaten HK, et al. Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites. Hum Genom. 2020;14(1):1\u20139.","journal-title":"Hum Genom"},{"issue":"4","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF01061407","volume":"2","author":"CG Reg\u00e5rdh","year":"1974","unstructured":"Reg\u00e5rdh CG, Borg KO, Johansson R, et al. Pharmacokinetic studies on the selective\u03b2 1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm. 1974;2(4):347\u201364.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"7","key":"1145_CR11","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1021\/jm401963n","volume":"57","author":"A Mateus","year":"2014","unstructured":"Mateus A, Matsson PR, Artursson P. A high-throughput cell-based method to predict the unbound drug fraction in the brain. J Med Chem. 2014;57(7):3005\u201310.","journal-title":"J Med Chem"},{"issue":"5","key":"1145_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2165\/00003495-198631050-00002","volume":"31","author":"P Benfield","year":"1986","unstructured":"Benfield P, Clissold SP, Brogden RN. Metoprolol. Drugs. 1986;31(5):376\u2013429.","journal-title":"Drugs"},{"issue":"6","key":"1145_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1365-2125.1981.tb01169.x","volume":"11","author":"G Neil-Dwyer","year":"1981","unstructured":"Neil-Dwyer G, Bartlett J, McAinsh J, et al. Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol. 1981;11(6):549\u201353.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1145_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13020-017-0157-6","volume":"13","author":"W Younis","year":"2018","unstructured":"Younis W, Asif H, Sharif A, et al. Traditional medicinal plants used for respiratory disorders in Pakistan: a review of the ethno-medicinal and pharmacological evidence. Chin Med. 2018;13(1):1\u201329.","journal-title":"Chin Med"},{"issue":"17","key":"1145_CR15","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","volume":"287","author":"KE Lasser","year":"2002","unstructured":"Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215\u201320.","journal-title":"JAMA"},{"issue":"5","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003088-198106050-00004","volume":"6","author":"C-G Reg\u00e5rdh","year":"1981","unstructured":"Reg\u00e5rdh C-G, Jord\u00f6 L, Ervik M, et al. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet. 1981;6(5):375\u201388.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1145_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00003088-198005020-00004","volume":"5","author":"L Jord\u00f6","year":"1980","unstructured":"Jord\u00f6 L, Attman P, Aurell M, et al. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980;5(2):169\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1145_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/bcp.14247","volume":"86","author":"M Meloche","year":"2020","unstructured":"Meloche M, Khazaka M, Kassem I, et al. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta-analysis. Br J Clin Pharmacol. 2020;86(6):1015\u201333.","journal-title":"Br J Clin Pharmacol"},{"key":"1145_CR19","unstructured":"Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org. 2011."},{"issue":"5","key":"1145_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"issue":"5","key":"1145_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0197-2456(99)00026-4","volume":"20","author":"HD Clark","year":"1999","unstructured":"Clark HD, Wells GA, Hu\u00ebt C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999;20(5):448\u201352.","journal-title":"Control Clin Trials"},{"issue":"Supplement 1","key":"1145_CR22","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.3233\/WOR-2012-1039-4218","volume":"41","author":"RMA Al-Dirini","year":"2012","unstructured":"Al-Dirini RMA, Thewlis D, Paul G. A comprehensive literature review of the pelvis and the lower extremity FE human models under quasi-static conditions. Work. 2012;41(Supplement 1):4218\u201329.","journal-title":"Work"},{"issue":"6","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/00005344-198011000-00002","volume":"2","author":"C-G Reg\u00e5rdh","year":"1980","unstructured":"Reg\u00e5rdh C-G, Johnsson G, Jord\u00f6 L, et al. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. J Cardiovasc Pharmacol. 1980;2(6):715\u201323.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"S2","key":"1145_CR24","doi-asserted-by":"publisher","first-page":"113S","DOI":"10.1111\/j.1365-2125.1985.tb02751.x","volume":"19","author":"J Godbillon","year":"1985","unstructured":"Godbillon J, Evard D, Vidon N, et al. Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon. Br J Clin Pharmacol. 1985;19(S2):113S-S118.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1145_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF03188836","volume":"19","author":"J Richard","year":"1994","unstructured":"Richard J, Cardot J, Godbillon J. Inter-and intra-subject variability of metoprolol kinetics after intravenous administration. Eur J Drug Metab Pharmacokinet. 1994;19(2):157\u201362.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF00544048","volume":"27","author":"M Larsson","year":"1984","unstructured":"Larsson M, Landahl S, Lundborg P, et al. Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment. Eur J Clin Pharmacol. 1984;27(2):217\u201322.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1145_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF00562615","volume":"17","author":"M Kendall","year":"1980","unstructured":"Kendall M, John V, Quarterman C, et al. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metoprolol. Eur J Clin Pharmacol. 1980;17(2):87\u201392.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1145_CR28","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/BF00578406","volume":"33","author":"A Sandberg","year":"1988","unstructured":"Sandberg A, Blomqvist I, Jonsson U, et al. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol. 1988;33(1):S9\u201314.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1145_CR29","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/BF00578407","volume":"33","author":"B Oosterhuis","year":"1988","unstructured":"Oosterhuis B, Jonkman J, Kerkhof F. Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation. Eur J Clin Pharmacol. 1988;33(1):S15\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"S2","key":"1145_CR30","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1002\/j.1552-4604.1990.tb03493.x","volume":"30","author":"B Oosterhuis","year":"1990","unstructured":"Oosterhuis B, Jonkman J, Zuiderwijk P, et al. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR\/ZOK with a conventional slow release preparation. J Clin Pharmacol. 1990;30(S2):S33\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"S2","key":"1145_CR31","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1002\/j.1552-4604.1990.tb03492.x","volume":"30","author":"I Wieselgren","year":"1990","unstructured":"Wieselgren I, Lundborg P, Sandberg A, et al. Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR\/ZOK) 50 mg in young subjects. J Clin Pharmacol. 1990;30(S2):S28\u201332.","journal-title":"J Clin Pharmacol"},{"issue":"S2","key":"1145_CR32","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1002\/j.1552-4604.1990.tb03491.x","volume":"30","author":"P L\u00fccker","year":"1990","unstructured":"L\u00fccker P, Moore G, Wieselgren I, et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR\/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol. 1990;30(S2):S17\u201327.","journal-title":"J Clin Pharmacol"},{"issue":"S2","key":"1145_CR33","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/j.1552-4604.1990.tb03494.x","volume":"30","author":"I Darmansjah","year":"1990","unstructured":"Darmansjah I, Wong E, Setiawati A, et al. Pharmacokinetic and pharmacodynamic properties of controlled release (CR\/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. J Clin Pharmacol. 1990;30(S2):S39\u201345.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1145_CR34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/BF00278584","volume":"38","author":"E Dimen\u00e4s","year":"1990","unstructured":"Dimen\u00e4s E, Dahl\u00f6f C, Heibel B, et al. Subjective symptoms and pharmacokinetics\/dynamics of metoprolol CR in elderly subjects\u2014a comparison with atenolol. Eur J Clin Pharmacol. 1990;38(6):571\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1145_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00315499","volume":"45","author":"P Lundborg","year":"1993","unstructured":"Lundborg P, Abrahamsson B, Wieselgren I, et al. The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers. Eur J Clin Pharmacol. 1993;45(2):161\u20133.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1145_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2710.2008.00945.x","volume":"33","author":"S Jin","year":"2008","unstructured":"Jin S, Chung H, Chung M, et al. Influence of CYP2D6* 10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J Clin Pharm Ther. 2008;33(5):567\u201373.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"1145_CR37","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1053\/cp.1999.v66.103400001","volume":"66","author":"AB Luzier","year":"1999","unstructured":"Luzier AB, Killian A, Wilton JH, et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 1999;66(6):594\u2013601.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1145_CR38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/(SICI)1520-636X(1999)11:7<591::AID-CHIR12>3.0.CO;2-T","volume":"11","author":"PM Cerqueira","year":"1999","unstructured":"Cerqueira PM, Cesarino EJ, Mateus FH, et al. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. Chirality. 1999;11(7):591\u20137.","journal-title":"Chirality"},{"issue":"3","key":"1145_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/BF00981121","volume":"31","author":"P Held","year":"1986","unstructured":"Held P, Reg\u00e5rdh C-G. Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study. Eur J Clin Pharmacol. 1986;31(3):261\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1145_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s002280050332","volume":"53","author":"B Everts","year":"1997","unstructured":"Everts B, Karlson B, Herlitz J, et al. Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. Eur J Clin Pharmacol. 1997;53(1):23\u201331.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1145_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2125.1982.tb04948.x","volume":"14","author":"M Kendall","year":"1982","unstructured":"Kendall M, Quarterman C, Jack D, et al. Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol. 1982;14(1):120.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1145_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/bdd.2510030107","volume":"3","author":"DB Jack","year":"1982","unstructured":"Jack DB, Kendall MJ, Dean S, et al. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol. Biopharm Drug Dispos. 1982;3(1):47\u201354.","journal-title":"Biopharm Drug Dispos"},{"issue":"S1","key":"1145_CR43","doi-asserted-by":"publisher","first-page":"29S","DOI":"10.1111\/j.1365-2125.1984.tb02425.x","volume":"17","author":"D Gangji","year":"1984","unstructured":"Gangji D, Juvent M, Niset G, et al. Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol. Br J Clin Pharmacol. 1984;17(S1):29S-35S.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1145_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2125.1985.tb02634.x","volume":"19","author":"J Kelly","year":"1985","unstructured":"Kelly J, Salem S, Kinney C, et al. Effects of ranitidine on the disposition of metoprolol. Br J Clin Pharmacol. 1985;19(2):219\u201324.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1145_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF00637630","volume":"33","author":"L Schaaf","year":"1987","unstructured":"Schaaf L, Campbell S, Mayersohn M, et al. Influence of smoking and gender on the disposition kinetics of metoprolol. Eur J Clin Pharmacol. 1987;33(4):355\u201361.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1145_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2125.1987.tb03164.x","volume":"24","author":"F Wagner","year":"1987","unstructured":"Wagner F, Kalusche D, Trenk D, et al. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987;24(2):213\u201320.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1145_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2036.1988.tb00726.x","volume":"2","author":"M Chellingsworth","year":"1988","unstructured":"Chellingsworth M, Laugher S, Akhlaghi S, et al. The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. Aliment Pharmacol Ther. 1988;2(6):521\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1145_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF00561026","volume":"36","author":"T Tateishi","year":"1989","unstructured":"Tateishi T, Nakashima H, Shitou T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmacol. 1989;36(1):67\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1145_CR49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1067\/mcp.2000.104788","volume":"67","author":"A Hemeryck","year":"2000","unstructured":"Hemeryck A, Lefebvre RA, De Vriendt C, et al. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 2000;67(3):283\u201391.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1145_CR50","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1067\/mcp.2000.106464","volume":"67","author":"BA Hamelin","year":"2000","unstructured":"Hamelin BA, Bouayad A, M\u00e9thot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000;67(5):466\u201377.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1145_CR51","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-2125.2000.00197.x","volume":"49","author":"M Somer","year":"2000","unstructured":"Somer M, Kallio J, Pesonen U, et al. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol. 2000;49(6):549\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1145_CR52","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0009-9236(03)00120-6","volume":"74","author":"U Werner","year":"2003","unstructured":"Werner U, Werner D, Rau T, et al. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74(2):130\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1145_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1472-8206.2003.00216.x","volume":"18","author":"T Damy","year":"2004","unstructured":"Damy T, Pousset F, Caplain H, et al. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18(1):113\u201323.","journal-title":"Fundam Clin Pharmacol"},{"issue":"10","key":"1145_CR54","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.amjcard.2004.07.125","volume":"94","author":"D Werner","year":"2004","unstructured":"Werner D, Wuttke H, Fromm MF, et al. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol. 2004;94(10):1319\u201321.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1145_CR55","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1124\/jpet.104.081109","volume":"313","author":"A Sharma","year":"2005","unstructured":"Sharma A, Pibarot P, Pilote S, et al. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther. 2005;313(3):1172\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1145_CR56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00228-007-0404-3","volume":"64","author":"K Goryachkina","year":"2008","unstructured":"Goryachkina K, Burbello A, Boldueva S, et al. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol. 2008;64(3):275\u201382.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1145_CR57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00004714-200702000-00005","volume":"27","author":"SH Preskorn","year":"2007","unstructured":"Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27(1):28\u201334.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"1145_CR58","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1365-2125.2008.03150.x","volume":"65","author":"Y Wang","year":"2008","unstructured":"Wang Y, Zhou L, Dutreix C, et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol. 2008;65(6):885\u201392.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1145_CR59","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1592\/phco.31.7.630","volume":"31","author":"RB Parker","year":"2011","unstructured":"Parker RB, Soberman JE. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy. 2011;31(7):630\u201341.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1145_CR60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3109\/00498254.2014.967824","volume":"45","author":"D-Y Cho","year":"2015","unstructured":"Cho D-Y, Bae SH, Lee JK, et al. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers. Xenobiotica. 2015;45(3):256\u201363.","journal-title":"Xenobiotica"},{"issue":"S2","key":"1145_CR61","doi-asserted-by":"publisher","first-page":"119S","DOI":"10.1111\/j.1365-2125.1985.tb02752.x","volume":"19","author":"D Evard","year":"1985","unstructured":"Evard D, Vidon N, Godbillon J, et al. Investigation of drug absorption from the gastrointestinal tract of man. IV. Influence of food and digestive secretions on metoprolol jejunal absorption. Br J Clin Pharmacol. 1985;19(S2):119S-S125.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01145-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T21:10:33Z","timestamp":1668460233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01145-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01145-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"17 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ammara Zamir, Iltaf Hussain, Anees ur Rehman, Waseem Ashraf, Imran, Hamid Saeed, Abdul Majeed, Faleh Alqahtani, and Muhammad Fawad Rasool declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the data used for this publication is either presented in the main article or is available as supplementary information.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}